Health Policy for Obesity and Metabolic Syndrome in Asian Health Systems: Three Design Principles, Three Binding Constraints, and the Governance That Decides between Them.

Authors

Sunyoung Kim, Sang Youl Rhee

Published in

Journal of obesity & metabolic syndrome. Oct 14, 2026. Epub Oct 14, 2026.

Abstract

Obesity drives metabolic syndrome and cardiometabolic disease in Asia, where complications develop at lower levels of adiposity than in Western populations. We reviewed Asian obesity policies to identify design features that support their durability and how access to incretin-based medications fits within these policies.
This narrative review used a structured search of PubMed/MEDLINE and Embase (January 2000 to March 2025) supplemented by grey literature from public health agencies. Of 1,884 records, 612 underwent full-text review and 236 met inclusion criteria. Two reviewers screened independently, resolving disagreements by consensus. Evidence was grouped into healthcare-based prevention and treatment, fiscal and regulatory measures, food and physical activity environments, digital health, and pharmacotherapy access.
We examined Japan's Specific Health Checkup, Korea's National Health Screening Program, Singapore's Nutri-Grade scheme, and sugar-sweetened beverage taxes in Thailand, Malaysia, and the Philippines. Three design principles emerged: holding insurers accountable for population metabolic screening, scheduling excise tax increases in advance, and adapting regulation to local food settings, including freshly prepared foods. Their effectiveness was limited by stigma in workplace screening, limited reach into the informal food sector, and lower uptake in rural and digitally underserved populations. Policy durability depended more on governance than on individual measures.
Obesity policy in Asia requires governance mechanisms built into its design: a permanent inter-agency body with protected funding, legal safeguards against industry interference, and mandatory equity audits with independent monitoring. Access to incretin-based medications belongs in the same framework; otherwise, these drugs may widen regional inequities.

PMID:
42869494
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.